Background
Phase III RCT (ACCORD 11/PRODIGE 4). 342 patients with metastatic pancreatic adenocarcinoma, PS 0-1, age ≤75, adequate organ function. Randomized 1:1 to FOLFIRINOX or gemcitabine. Established FOLFIRINOX as a standard first-line regimen for fit patients with metastatic disease.
Interventions and follow up
Arm A: FOLFIRINOX — oxaliplatin 85 mg/m², leucovorin 400 mg/m², irinotecan 180 mg/m², 5-FU 400 mg/m² bolus then 2,400 mg/m² over 46h every 2 weeks
Arm B: Gemcitabine 1,000 mg/m² over 30 minutes weekly ×7, then weekly ×3 every 4 weeks
Primary endpoint: Overall survival
Median follow-up: 26.6 months
Arm B: Gemcitabine 1,000 mg/m² over 30 minutes weekly ×7, then weekly ×3 every 4 weeks
Primary endpoint: Overall survival
Median follow-up: 26.6 months
Results
mOS: 11.1 months (FOLFIRINOX) vs 6.8 months (gemcitabine), HR 0.57, 95% CI 0.45–0.73, P<.001
mPFS: 6.4 vs 3.3 months, HR 0.47, P<.001
ORR: 31.6% vs 9.4%, P<.001
mPFS: 6.4 vs 3.3 months, HR 0.47, P<.001
ORR: 31.6% vs 9.4%, P<.001
Adverse events
Hematologic: Grade ≥3 neutropenia 45.7% vs 21.0%, febrile neutropenia 5.4% vs 1.2%; G-CSF required in 42.5% of FOLFIRINOX patients.
Non-hematologic: Grade ≥3 neuropathy 9.0% vs 0%, diarrhea 12.7% vs 1.8%, fatigue 23.6% vs 17.8%.
Non-hematologic: Grade ≥3 neuropathy 9.0% vs 0%, diarrhea 12.7% vs 1.8%, fatigue 23.6% vs 17.8%.
Conclusions
FOLFIRINOX nearly doubled OS versus gemcitabine in fit patients with metastatic pancreatic cancer (11.1 vs 6.8 months, HR 0.57), with substantially higher response rates (31.6% vs 9.4%). This established FOLFIRINOX as the preferred first-line regimen for PS 0-1 patients with metastatic pancreatic adenocarcinoma.
Key Limitations
Restricted to PS 0-1, age ≤75, and adequate biliary drainage — not applicable to unfit patients. High toxicity profile requires careful patient selection and monitoring. Full-dose FOLFIRINOX was used; subsequent PRODIGE-24 used modified FOLFIRINOX (reduced irinotecan, no 5-FU bolus) with better tolerability. Patients with PS ≥2 are better served by gemcitabine-based therapy (MPACT or gemcitabine monotherapy).
Clinical Context
ACCORD 11/PRODIGE 4 transformed management of metastatic pancreatic cancer. FOLFIRINOX and nab-paclitaxel + gemcitabine (MPACT) are the two standard first-line options for fit patients (per ESMO/ASCO); FOLFIRINOX is preferred when more aggressive systemic therapy is needed. Modified FOLFIRINOX (irinotecan 150 mg/m², no bolus 5-FU) is increasingly used for better tolerability in both metastatic and adjuvant settings.
References